348 related articles for article (PubMed ID: 23945500)
1. Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.
Vinken M; Landesmann B; Goumenou M; Vinken S; Shah I; Jaeschke H; Willett C; Whelan M; Rogiers V
Toxicol Sci; 2013 Nov; 136(1):97-106. PubMed ID: 23945500
[TBL] [Abstract][Full Text] [Related]
2. The adverse outcome pathway concept: a pragmatic tool in toxicology.
Vinken M
Toxicology; 2013 Oct; 312():158-65. PubMed ID: 23978457
[TBL] [Abstract][Full Text] [Related]
3. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
Fattinger K; Funk C; Pantze M; Weber C; Reichen J; Stieger B; Meier PJ
Clin Pharmacol Ther; 2001 Apr; 69(4):223-31. PubMed ID: 11309550
[TBL] [Abstract][Full Text] [Related]
4. Adverse outcome pathway development from protein alkylation to liver fibrosis.
Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.
Köck K; Ferslew BC; Netterberg I; Yang K; Urban TJ; Swaan PW; Stewart PW; Brouwer KL
Drug Metab Dispos; 2014 Apr; 42(4):665-74. PubMed ID: 24154606
[TBL] [Abstract][Full Text] [Related]
6. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Dawson S; Stahl S; Paul N; Barber J; Kenna JG
Drug Metab Dispos; 2012 Jan; 40(1):130-8. PubMed ID: 21965623
[TBL] [Abstract][Full Text] [Related]
8. Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury.
Gijbels E; Vilas-Boas V; Annaert P; Vanhaecke T; Devisscher L; Vinken M
Arch Toxicol; 2020 Apr; 94(4):1151-1172. PubMed ID: 32152650
[TBL] [Abstract][Full Text] [Related]
9. Current Concepts in Drug-Induced Bile Salt Export Pump (BSEP) Interference.
Kenna JG
Curr Protoc Toxicol; 2014 Aug; 61():23.7.1-15. PubMed ID: 25104267
[TBL] [Abstract][Full Text] [Related]
10. BSEP inhibition: in vitro screens to assess cholestatic potential of drugs.
Kis E; Ioja E; Rajnai Z; Jani M; Méhn D; Herédi-Szabó K; Krajcsi P
Toxicol In Vitro; 2012 Dec; 26(8):1294-9. PubMed ID: 22120137
[TBL] [Abstract][Full Text] [Related]
11. Geniposidic acid protected against ANIT-induced hepatotoxity and acute intrahepatic cholestasis, due to Fxr-mediated regulation of Bsep and Mrp2.
Chen H; Huang X; Min J; Li W; Zhang R; Zhao W; Liu C; Yi L; Mi S; Wang N; Wang Q; Zhu C
J Ethnopharmacol; 2016 Feb; 179():197-207. PubMed ID: 26723467
[TBL] [Abstract][Full Text] [Related]
12. Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump.
Sakurai A; Kurata A; Onishi Y; Hirano H; Ishikawa T
Expert Opin Drug Saf; 2007 Jan; 6(1):71-86. PubMed ID: 17181454
[TBL] [Abstract][Full Text] [Related]
13. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Morgan RE; Trauner M; van Staden CJ; Lee PH; Ramachandran B; Eschenberg M; Afshari CA; Qualls CW; Lightfoot-Dunn R; Hamadeh HK
Toxicol Sci; 2010 Dec; 118(2):485-500. PubMed ID: 20829430
[TBL] [Abstract][Full Text] [Related]
14. Disruption of BSEP Function in HepaRG Cells Alters Bile Acid Disposition and Is a Susceptive Factor to Drug-Induced Cholestatic Injury.
Qiu X; Zhang Y; Liu T; Shen H; Xiao Y; Bourner MJ; Pratt JR; Thompson DC; Marathe P; Humphreys WG; Lai Y
Mol Pharm; 2016 Apr; 13(4):1206-16. PubMed ID: 26910619
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump.
Rodrigues AD; Lai Y; Cvijic ME; Elkin LL; Zvyaga T; Soars MG
Drug Metab Dispos; 2014 Apr; 42(4):566-74. PubMed ID: 24115749
[TBL] [Abstract][Full Text] [Related]
16. The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.
Guo YX; Xu XF; Zhang QZ; Li C; Deng Y; Jiang P; He LY; Peng WX
Toxicol Mech Methods; 2015; 25(5):382-7. PubMed ID: 25886055
[TBL] [Abstract][Full Text] [Related]
17. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis.
Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX
Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198
[TBL] [Abstract][Full Text] [Related]
18. In vitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review.
Cheng Y; Woolf TF; Gan J; He K
Chem Biol Interact; 2016 Aug; 255():23-30. PubMed ID: 26683212
[TBL] [Abstract][Full Text] [Related]
19. Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.
Vinken M
Methods Mol Biol; 2016; 1425():325-37. PubMed ID: 27311472
[TBL] [Abstract][Full Text] [Related]
20. Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human.
Jemnitz K; Veres Z; Vereczkey L
Toxicol Sci; 2010 May; 115(1):80-8. PubMed ID: 20147439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
